Nifty
:
22780.25
Sensex
:
72771.72
-360.25 (-1.56%)
-1124.02 (-1.52%)
Nifty
Sensex
:
:
22780.25
72771.72
-360.25 (-1.56%)
-1124.02 (-1.52%)

Natco Pharma Ltd.

Pharmaceuticals & Drugs - Global

Rating :
58/99

BSE: 524816 | NSE: NATCOPHARM

NSE BSE
828.55
28-Sep-2026
  • Open
  • High
  • Low
  • Previous Close
  •  840.8
  •  857.85
  •  823
  •  839.30
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  502079
  •  418093751.45
  •  1226.8
  •  789

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 14,832.09
  • 12.96
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 13,987.59
  • 0.60%
  • 1.59

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 49.42%
  • 1.53%
  • 23.41%
  • FII
  • DII
  • Others
  • 16.99%
  • 5.56%
  • 3.09%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.28
  • 15.96
  • 0.66

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.71
  • 40.38
  • -3.89

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.94
  • 51.84
  • -0.40

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.42
  • 15.08
  • 12.32

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.02
  • 2.71
  • 2.59

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.18
  • 14.02
  • 8.48

Earnings Forecasts:

(Updated: 27-09-2026)
Description
2026
2027
2028
2029
Adj EPS
79.2
41.82
52.85
57.19
P/E Ratio
10.46
19.81
15.68
14.49
Revenue
4078.3
3252.1
3721.78
4042.18
EBITDA
1436.5
773.4
986.68
1069.8
Net Income
1418.5
750.69
939.06
1025.5
ROA
14.4
6.33
7.41
6.44
P/B Ratio
1.61
1.50
1.39
1.29
ROE
16.86
7.72
8.99
9.19
FCFF
1628.9
584.53
327.52
2250.86
FCFF Yield
11.92
4.28
2.4
16.47
Net Debt
-1415.2
-1887.33
-2373.5
-2642.05
BVPS
514.83
551.14
594.36
643.94

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 26
Jun 25
Var%
Mar 26
Mar 25
Var%
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Net Sales
735.20
1,328.90
-44.68%
739.10
1,221.00
-39.47%
647.30
474.80
36.33%
1,363.00
1,371.10
-0.59%
Expenses
548.70
757.90
-27.60%
611.50
672.90
-9.12%
488.60
436.00
12.06%
783.80
566.80
38.29%
EBITDA
186.50
571.00
-67.34%
127.60
548.10
-76.72%
158.70
38.80
309.02%
579.20
804.30
-27.99%
EBIDTM
25.37%
42.97%
17.26%
44.89%
24.52%
8.17%
42.49%
58.66%
Other Income
59.20
61.70
-4.05%
77.80
66.30
17.35%
58.10
176.30
-67.04%
100.00
63.80
56.74%
Interest
13.00
3.20
306.25%
10.90
10.20
6.86%
9.50
4.40
115.91%
13.10
4.10
219.51%
Depreciation
47.10
57.60
-18.23%
50.40
98.30
-48.73%
46.20
47.00
-1.70%
52.40
45.80
14.41%
PBT
185.60
571.90
-67.55%
144.10
505.90
-71.52%
161.10
163.70
-1.59%
613.70
818.20
-24.99%
Tax
63.40
91.60
-30.79%
-89.20
99.90
-
20.70
31.30
-33.87%
95.80
141.70
-32.39%
PAT
122.20
480.30
-74.56%
233.30
406.00
-42.54%
140.40
132.40
6.04%
517.90
676.50
-23.44%
PATM
16.62%
36.14%
31.57%
33.25%
21.69%
27.89%
38.00%
49.34%
EPS
11.54
26.85
-57.02%
14.97
22.72
-34.11%
8.46
7.43
13.86%
28.96
37.84
-23.47%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Net Sales
3,484.60
4,078.30
4,429.50
3,998.80
2,707.10
1,944.80
2,052.10
1,915.00
2,094.50
2,184.80
2,020.20
Net Sales Growth
-20.73%
-7.93%
10.77%
47.72%
39.20%
-5.23%
7.16%
-8.57%
-4.13%
8.15%
 
Cost Of Goods Sold
605.00
615.60
641.50
667.90
583.20
528.40
483.70
354.40
332.70
411.10
599.10
Gross Profit
2,879.60
3,462.70
3,788.00
3,330.90
2,123.90
1,416.40
1,568.40
1,560.60
1,761.80
1,773.70
1,421.10
GP Margin
82.64%
84.91%
85.52%
83.30%
78.46%
72.83%
76.43%
81.49%
84.12%
81.18%
70.34%
Total Expenditure
2,432.60
2,641.80
2,235.70
2,247.40
1,795.40
1,681.30
1,448.30
1,332.40
1,299.70
1,256.40
1,336.80
Power & Fuel Cost
-
96.90
93.10
88.90
81.90
76.40
61.10
62.40
59.60
56.20
50.50
% Of Sales
-
2.38%
2.10%
2.22%
3.03%
3.93%
2.98%
3.26%
2.85%
2.57%
2.50%
Employee Cost
-
687.20
594.50
525.00
486.70
444.80
414.90
375.00
355.90
325.60
243.20
% Of Sales
-
16.85%
13.42%
13.13%
17.98%
22.87%
20.22%
19.58%
16.99%
14.90%
12.04%
Manufacturing Exp.
-
560.50
374.80
368.40
279.60
353.60
291.90
243.30
276.40
182.60
169.70
% Of Sales
-
13.74%
8.46%
9.21%
10.33%
18.18%
14.22%
12.70%
13.20%
8.36%
8.40%
General & Admin Exp.
-
376.20
304.00
313.00
208.80
152.80
116.70
132.60
126.40
105.50
88.10
% Of Sales
-
9.22%
6.86%
7.83%
7.71%
7.86%
5.69%
6.92%
6.03%
4.83%
4.36%
Selling & Distn. Exp.
-
173.20
136.40
153.00
96.10
43.70
34.40
98.10
90.00
136.90
143.20
% Of Sales
-
4.25%
3.08%
3.83%
3.55%
2.25%
1.68%
5.12%
4.30%
6.27%
7.09%
Miscellaneous Exp.
-
132.20
91.40
131.20
59.10
81.60
45.60
66.60
58.70
38.50
143.20
% Of Sales
-
3.24%
2.06%
3.28%
2.18%
4.20%
2.22%
3.48%
2.80%
1.76%
2.13%
EBITDA
1,052.00
1,436.50
2,193.80
1,751.40
911.70
263.50
603.80
582.60
794.80
928.40
683.40
EBITDA Margin
30.19%
35.22%
49.53%
43.80%
33.68%
13.55%
29.42%
30.42%
37.95%
42.49%
33.83%
Other Income
295.10
297.60
356.70
128.10
128.50
99.00
106.00
107.40
130.20
40.40
13.90
Interest
46.50
36.70
23.90
19.20
14.50
17.70
13.30
21.50
19.30
15.40
18.50
Depreciation
196.10
206.60
235.20
186.80
163.80
142.60
116.90
99.80
81.00
66.20
54.40
PBT
1,104.50
1,490.80
2,291.40
1,673.50
861.90
202.20
579.60
568.70
824.70
887.20
624.40
Tax
90.70
118.90
408.00
285.20
146.60
32.20
137.20
110.60
182.30
192.00
139.50
Tax Rate
8.21%
7.98%
17.81%
17.04%
17.01%
15.92%
23.67%
19.45%
22.11%
21.64%
22.34%
PAT
1,013.80
1,371.90
1,885.40
1,388.30
715.30
170.00
440.90
460.80
644.40
696.20
486.00
PAT before Minority Interest
1,013.40
1,371.90
1,883.40
1,388.30
715.30
170.00
442.40
458.10
642.40
695.20
484.90
Minority Interest
-0.40
0.00
2.00
0.00
0.00
0.00
-1.50
2.70
2.00
1.00
1.10
PAT Margin
29.09%
33.64%
42.56%
34.72%
26.42%
8.74%
21.49%
24.06%
30.77%
31.87%
24.06%
PAT Growth
-40.20%
-27.24%
35.81%
94.09%
320.76%
-61.44%
-4.32%
-28.49%
-7.44%
43.25%
 
EPS
56.61
76.60
105.27
77.52
39.94
9.49
24.62
25.73
35.98
38.87
27.14

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Shareholder's Funds
9,221.10
7,607.00
5,853.10
4,873.80
4,263.60
4,121.60
3,773.50
3,489.00
3,072.20
1,649.30
Share Capital
35.80
35.80
35.80
36.50
36.50
36.50
36.40
36.50
36.90
34.90
Total Reserves
9,185.30
7,571.20
5,817.30
4,837.30
4,223.70
4,067.60
3,713.60
3,421.70
3,011.40
1,599.00
Non-Current Liabilities
-60.90
24.90
61.00
100.50
135.10
142.90
117.80
83.40
47.10
37.70
Secured Loans
100.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Provisions
61.80
65.60
70.90
85.30
95.70
99.60
90.20
71.00
32.40
21.90
Current Liabilities
1,680.90
943.50
972.80
683.10
710.40
525.60
685.30
728.70
592.00
626.50
Trade Payables
409.30
274.90
235.50
263.80
161.80
146.20
255.40
217.00
269.10
262.70
Other Current Liabilities
614.50
238.60
238.90
227.30
126.70
99.50
96.70
109.80
133.40
127.10
Short Term Borrowings
306.40
273.10
363.20
165.00
404.00
265.80
314.20
386.30
173.20
221.60
Short Term Provisions
350.70
156.90
135.20
27.00
17.90
14.10
19.00
15.60
16.30
15.10
Total Liabilities
10,841.10
8,580.70
6,886.90
5,657.40
5,109.10
4,791.90
4,587.80
4,303.10
3,715.10
2,317.60
Net Block
2,802.70
2,698.00
2,490.80
2,426.90
2,311.80
2,023.20
1,584.40
1,227.20
1,018.60
833.00
Gross Block
4,255.70
4,015.20
3,603.20
3,375.10
3,126.90
2,702.10
2,148.70
1,694.50
1,407.60
1,158.70
Accumulated Depreciation
1,403.00
1,267.20
1,112.40
948.20
815.10
678.90
564.30
467.30
389.00
325.70
Non Current Assets
5,788.80
3,310.70
2,863.40
2,657.10
2,622.40
2,447.10
2,262.20
1,955.90
1,584.40
1,230.30
Capital Work in Progress
293.70
225.40
137.30
64.30
129.50
223.40
518.00
637.60
480.00
336.30
Non Current Investment
2,548.90
152.80
95.90
87.30
104.40
151.90
83.60
19.90
8.10
0.10
Long Term Loans & Adv.
100.80
73.80
112.70
78.30
72.00
44.30
72.00
62.80
69.60
54.90
Other Non Current Assets
42.70
160.70
26.70
0.30
4.70
4.30
4.20
8.40
8.10
6.00
Current Assets
5,052.30
5,270.00
4,023.50
3,000.30
2,486.70
2,344.80
2,325.60
2,347.20
2,130.70
1,087.30
Current Investments
578.20
320.80
443.50
305.00
203.70
151.80
28.70
148.70
68.40
32.10
Inventories
908.50
765.80
700.50
742.90
762.00
798.20
558.00
529.00
438.40
348.90
Sundry Debtors
881.20
1,246.60
1,188.90
856.10
620.60
412.90
551.30
506.20
637.50
475.20
Cash & Bank
1,550.90
2,176.00
952.90
546.30
206.10
283.50
66.00
279.50
183.70
35.80
Other Current Assets
1,133.50
135.10
99.50
64.40
694.30
698.40
1,121.60
883.80
802.70
195.30
Short Term Loans & Adv.
1,031.10
625.70
638.20
485.60
606.20
603.70
1,030.00
776.40
749.50
169.50
Net Current Assets
3,371.40
4,326.50
3,050.70
2,317.20
1,776.30
1,819.20
1,640.30
1,618.50
1,538.70
460.80
Total Assets
10,841.10
8,580.70
6,886.90
5,657.40
5,109.10
4,791.90
4,587.80
4,303.10
3,715.10
2,317.60

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Cash From Operating Activity
1,768.30
1,696.80
1,211.60
849.10
46.50
298.80
417.30
668.80
463.60
345.80
PBT
1,490.80
2,291.40
1,673.50
861.90
202.20
579.60
568.70
824.70
887.20
624.40
Adjustment
29.70
-22.30
133.80
102.00
123.90
62.10
54.00
14.30
75.60
100.20
Changes in Working Capital
645.50
-199.70
-309.40
62.70
-231.40
-212.90
-97.60
8.60
-294.60
-253.00
Cash after chg. in Working capital
2,166.00
2,069.40
1,497.90
1,026.60
94.70
428.80
525.10
847.60
668.20
471.60
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-397.70
-372.60
-286.30
-177.50
-48.20
-130.00
-107.80
-178.80
-204.60
-125.80
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-2,081.70
-1,414.50
-1,032.70
-477.10
-5.30
-103.30
-167.00
-612.20
-1,115.50
-299.40
Net Fixed Assets
-278.30
-515.60
-273.50
-113.40
-204.80
-250.20
-335.80
-436.10
-392.40
-299.40
Net Investments
-2,409.80
-113.40
-84.20
-107.50
-213.00
-145.90
53.30
-94.80
-54.80
-1.00
Others
606.40
-785.50
-675.00
-256.20
412.50
292.80
115.50
-81.30
-668.30
1.00
Cash from Financing Activity
297.50
-210.70
-246.90
-363.00
34.80
-185.70
-250.80
-50.90
650.90
-47.70
Net Cash Inflow / Outflow
-15.90
71.60
-68.00
9.00
76.00
9.80
-0.50
5.70
-1.00
-1.30
Opening Cash & Equivalents
120.00
70.40
131.90
111.10
25.80
19.80
28.30
21.70
23.50
24.20
Closing Cash & Equivalent
198.90
120.00
70.40
131.90
111.10
25.80
19.80
28.30
21.70
23.50

Financial Ratios

Consolidated /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Book Value (Rs.)
515.15
424.97
326.99
267.06
233.44
224.88
206.04
189.49
165.22
93.63
ROA
14.13%
24.35%
22.13%
13.29%
3.43%
9.43%
10.30%
16.02%
23.05%
23.43%
ROE
16.30%
27.98%
25.88%
15.66%
4.06%
11.27%
12.71%
19.75%
29.70%
33.21%
ROCE
17.16%
32.85%
30.08%
18.06%
4.86%
13.99%
14.82%
23.71%
35.28%
39.21%
Fixed Asset Turnover
1.14
1.25
1.24
0.89
0.76
0.86
1.07
1.47
1.72
1.93
Receivable days
82.64
93.30
86.16
93.53
85.10
84.44
93.77
91.36
92.22
65.12
Inventory Days
65.03
56.17
60.81
95.32
128.47
118.77
96.38
77.28
65.25
62.41
Payable days
202.84
145.20
136.43
133.18
106.38
151.52
65.96
72.53
81.42
78.30
Cash Conversion Cycle
-55.16
4.27
10.54
55.67
107.20
51.68
124.19
96.11
76.05
49.23
Total Debt/Equity
0.08
0.04
0.06
0.03
0.09
0.06
0.08
0.11
0.06
0.14
Interest Cover
41.62
96.87
88.16
60.44
12.42
44.58
27.45
43.73
58.61
34.75

Annual Reports:

FY 2026
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017

News Update:


  • USFDA completes inspection at Natco Pharma’s FDF manufacturing plant in Visakhapatnam
    22nd Aug 2026, 14:59 PM

    USFDA has conducted inspection from August 17, 2026- August 21, 2026

    Read More
  • Natco Pharma - Quarterly Results
    15th Aug 2026, 00:00 AM

    Read More
  • Natco Pharma gets USFDA's tentative approval for Olaparib tablets
    20th Jul 2026, 09:05 AM

    NATCO will be manufacturing Olaparib tablets and its partner Alembic, would be distributing the product in the U.S

    Read More
  • Natco Pharma completes acquisition of additional 13.25% stake in Adcock Ingram
    14th Jul 2026, 13:05 PM

    With the completion of this transaction, Natco’s shareholding in Adcock Ingram has increased from 35.75% to 49%

    Read More
  • Natco Pharma gets nod to raise stake in Adcock Ingram to 49%
    8th Jul 2026, 15:43 PM

    The acquisition is valued at Rs 1,069 crore at the prevailing exchange rate

    Read More
  • Natco Pharma gets nod to invest up to Rs 1,400 crore in NPSAPL
    8th Jul 2026, 14:22 PM

    The investment is expected to be completed before the end of July of 2026

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.